Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited are Dominating in the U.S. Multiple Myeloma Drugs Market in 2020

The U.S. Multiple Myeloma Drugs Market is expected to grow with the CAGR of 12.2% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/us-multiple-myeloma-drugs-market

The U.S. multiple myeloma drugs market is a highly consolidated market which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in the U.S. multiple myeloma drugs market are introducing strong range of product portfolio. This has helped the companies to maximize the sales with enhanced product portfolio. For instance, in November 2020, Bristol-Myers Squibb Company had announced the settlement of the U.S. Patent Litigation for Revlimid with Cipla. The initiative by the company would result in improved range of product portfolio of oncology section in the U.S. along with the rise in revenue and it would deliver a positive growth in the market.

Bristol-Myers Squibb Company is the dominating player in the U.S. multiple myeloma drugs market. The other key players existing in the multiple myeloma drugs market includes Karyopharm, AstraZeneca, Novartis AG, GlaxoSmithKline plc, AbbVie Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc., Dr. Reddy’s Laboratories Ltd., OncoPep, Inc., sanofi-aventis U.S. LLC (a subsidiary of Sanofi), Amgen Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. among others.

U.S. Multiple Myeloma Drugs Market

Bristol-Myers Squibb Company:

Bristol-Myers Squibb Company is headquartered in New York, U.S. and was founded in 1887. The company is focused on discovering, developing and delivering transformational medicines in areas where we believe we have an opportunity to make a meaningful difference for patients dealing with oncology, immunoscience, cardiovascular and fibrosis. The company deals in multiple business segments such as ORENCIA, other, total pharmaceuticals and prioritized brands among which prioritized brands is the market focused segment. The company provides products such as medical, aesthetic, surgical abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), AZACTAM (aztreonam for injection, USP), breyanzi (lisocabtagene maraleucel), baraclude (entecavir), droxia (hydroxyurea), eliquis (apixaban), empliciti (elotuzumab), evotaz (atazanavir and cobicistat), hydrea (hydroxyurea), IDHIFA (enasidenib), inrebic (fedratinib), istodax (romidepsin), kenalog-10 (triamcinolone acetonide), nulojix (belatacept), onureg (azacitidine tablets), opdivo (nivolumab), orencia (abatacept), pravachol (pravastatin sodium), pomalyst (pomalidomide) and reblozyl (luspatercept-Aamt) out of which empliciti (phase III), IDE-CEL (phase I), revlimid (lenalidomide) (phase III), opdivo (phase II), BCMA ADC, BCMA TCE, BCMA NEX T and GPRC5D are the market focused products.

For instance,

  • In September 2020, Bristol-Myers Squibb Company had announced that the FDA had accepted the approval for Priority Review their Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121), the companies’ investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with multiple myeloma. The initiative by the company would result in swift distribution of the drug in diagnostics center in the U.S. along with the rise in sales and it would deliver a positive growth in the market.

The company has presence in North America, Europe and Asia Pacific. The company has various subsidiaries namely Bristol-Myers Squibb Investco, L.L.C. (U.S.) Bristol-Myers Squibb Luxembourg International S.C.A. (Luxembourg), Bristol-Myers Squibb Marketing Services S.R.L. (Luxembourg) among others.

Janssen Pharmaceuticals, Inc.:

Janssen Pharmaceuticals, Inc. is headquartered in New Jersey, U.S. and was founded in 1886. The company is focused on providing the high quality products and the services to doctors, patients and other consumers. The company deals in multiple business segments such as consumer, pharmaceutical and medical devices among which pharmaceutical is the market focused segment. The company provides products under categories such as consumer health products, medical devices and pharmaceuticals products out of which pharmaceuticals products is the market focused category.

For instance,

  • In December 2020, Janssen Pharmaceuticals, Inc. had proclaimed the proposal of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, to cure refractory multiple myeloma, in Raritan New Jersey. The license submitted by the company would result in collaboration between various R&D teams, it would enhance the process of clinical trials, result in rapid distribution of the monoclonal antibodies across hospitals, diagnostic centers and it would exhibit a positive growth in the market.

The company has wide global presence across Asia-Pacific, Europe, Americas and Middle East and Africa. The company has several subsidiaries namely Janssen Pharmaceutica (Belgium), Neutrogena (U.S.), DePuy Synthes Companies (U.S.), Ethicon Inc. (U.S.), ALZA Corporation (U.S.) among others.                          

Takeda Pharmaceutical Company Limited:

Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan and was founded in 1781. The company is focused on developing and delivering vaccines that tackle the toughest problems in public health and improve the lives of people around the world. The company provides products under categories such as oncology, rare diseases, neuroscience and gastroenterology (GI) out of which oncology is the market focused category.

For instance,

  • In September 2020, Takeda Pharmaceutical Company Limited had declared the Phase 3 Clinical Trial Evaluation of NINLARO (Ixazomib) to treat multiple myeloma in Japan. The data was presented at the virtual scientific meeting of the Society of Hematologic Oncology (SOHO). The initiative by the company would lead to brand recognition, rise in drug portfolio, rise in sales and it would deliver a positive growth in the market.

The company has wide global presence across the Asia-Pacific, Europe, Middle East and Africa, South America and North America. The company also generates its revenue through various subsidiaries such as Takeda Oncology (U.S.), Takeda Pharmaceuticals U.S.A., Inc. (U.S.), TiGenix (Belgium), PVP Biologics, Inc. (Seattle), Takeda Consumer Healthcare Company Limited (Japan) among others.